PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Shows the trajectory of a company's cash-generation capacity. Consistent growth in operating and free cash flow suggests a robust, self-funding business model—crucial for value investors seeking undervalued, cash-rich opportunities.
12.55%
Net income growth under 50% of CRVO's 201.76%. Michael Burry would suspect deeper structural issues in generating bottom-line growth.
-4.31%
Negative yoy D&A while CRVO is 0.00%. Joel Greenblatt would note a short-term EPS advantage unless competitor invests for future advantage.
-1173.94%
Negative yoy deferred tax while CRVO stands at 0.00%. Joel Greenblatt would consider near-term tax obligations but a possible advantage if competitor's deferrals become a burden later.
-7.99%
Both cut yoy SBC, with CRVO at -45.28%. Martin Whitman would view it as an industry shift to reduce stock-based pay or a sign of reduced expansions.
214.02%
Well above CRVO's 374.38% if positive yoy. Michael Burry would see a risk of bigger working capital demands vs. competitor, harming free cash flow.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-138.21%
Negative yoy AP while CRVO is 301.99%. Joel Greenblatt would see quicker payments or less reliance on trade credit than competitor, unless expansions are hindered.
259.96%
Some yoy usage while CRVO is negative at -678.73%. John Neff would see competitor possibly generating more free cash from minor accounts than we do.
1173.94%
Some yoy increase while CRVO is negative at -434.58%. John Neff would see competitor possibly reining in intangible charges or revaluations more effectively than we do.
18.46%
Operating cash flow growth below 50% of CRVO's 202.14%. Michael Burry would see a serious shortfall in day-to-day cash profitability.
36.17%
CapEx growth of 36.17% while CRVO is zero at 0.00%. Bruce Berkowitz would see a mild cost burden that must yield returns in future revenue or margins.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
36.17%
We have mild expansions while CRVO is negative at -516.67%. John Neff sees competitor possibly divesting or pausing expansions more aggressively.
No Data
No Data available this quarter, please select a different quarter.
-70.77%
Negative yoy issuance while CRVO is 0.00%. Joel Greenblatt sees a near-term advantage in avoiding dilution unless competitor invests more effectively with the new shares.
No Data
No Data available this quarter, please select a different quarter.